For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 21,866,071 | |||
| General and administrative expenses | 6,102,374 | |||
| Total operating expenses | 27,968,445 | |||
| Loss from operations | -27,968,445 | |||
| Loss on debt conversion with related party | -6,134,120 | |||
| Loss on fixed asset disposal | -2,731 | |||
| Interest income (expense), net | 96,938 | |||
| Exchange loss, net | -27,916 | |||
| Total other expense | -6,067,829 | |||
| Loss before income taxes | -34,036,274 | |||
| Deferred income tax (expense) benefit | 221,096 | |||
| Net loss | -34,257,370 | |||
| Accrual of paid-in-kind dividends on series a non-voting convertible preferred stock | -1,256,662 | |||
| Net loss attributable to common stockholders | -35,514,032 | |||
| Basic EPS | -7.13 | |||
| Diluted EPS | -7.13 | |||
| Basic Average Shares | 4,977,446 | |||
| Diluted Average Shares | 4,977,446 | |||
Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. (DWTX)